aTYR PHARMA Files 8-K Report

TL;DR

aTYR PHARMA filed an 8-K on 7/22. Other Events.

AI Summary

On July 22, 2024, aTYR PHARMA, INC. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This 8-K filing signals a material event or change for aTYR PHARMA, INC., requiring disclosure to investors and the public.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not contain specific financial or operational disclosures that would immediately indicate high risk.

Key Numbers

• 001-37378 — Commission File Number (Identifies the company's SEC filings)
• 20-3435077 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• aTYR PHARMA, INC. (company) — Registrant
• July 22, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• San Diego, CA (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ATYR The Nasdaq Capital M

Filing Documents

• atyr-20240722.htm (8-K) — 44KB
• 0000950170-24-085058.txt ( ) — 158KB
• atyr-20240722.xsd (EX-101.SCH) — 26KB
• atyr-20240722_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On July 22, 2024, aTyr Pharma, Inc. (the "Company") announced that it has completed enrollment in its global pivotal Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis (the "EFZO-FIT study"). The EFZO-FIT study enrolled 268 patients at 85 centers in 9 countries, exceeding target enrollment. Topline data from the EFZO-FIT study are expected in the third quarter of 2025.

Forward-Looking Statements

Forward-Looking Statements Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements regarding the anticipated timing and results of data from the Company's Phase 3 EFZO-FIT study. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with research and development of pharmaceutical product candidates, as well as risks and uncertainties inherent in the Company's business, including those described in the Company's other filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATYR PHARMA, INC. By: /s/ Jill M. Broadfoot Jill M. Broadfoot Chief Financial Officer Date: July 22, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR